Additionally, phenome-wide Mendelian randomization (Phewas) analysis indicated potential therapeutic benefits of targeting GCKR, such as reducing the risk of pure hypercholesterolemia and alcohol intake frequency. This evidence concerns the gene GCKR and Hypercholesterolemia.